bionomics

1 - 12 of 30
Sort by: popularity | newest
Page  2 3  of 3 | Next
Bionomics

A novel method of treating anxiety disorders

QuickView | Pharmaceutical & healthcare | 18 Dec 2017

Bionomics’ lead programme is BNC210 for the treatment of anxiety-related disorders. The drug is an orally bioavailable small molecule targeting the α7 nicotinic acetylcholine receptor, which has been implicated in the brain’s response to anxiety. It is currently being tested in a randomized, double-blind Phase IIb clinical study of 192 post-traumatic stress disorder (PTSD) patients, with top-line results expected in H218.

Anteo Diagnostics

ASX Spotlight conference book May 2015

Sector Commentary: | *Multiple Sectors | 22 May 2015

-

Bionomics

Increasingly integrated business

Outlook | Pharmaceutical & healthcare | 09 Feb 2015

Bionomics has announced a number of strategic initiatives in recent months. In mid-2014, it entered into a second partnered programme with Merck & Co. In October, it acquired Prestwick Chemical, reinforcing its early-stage drug delivery and discovery functions. More recently, Bionomics secured a loan of US$10m to finance the development of BNC210, which it reacquired from Ironwood Pharma, starting a Phase Ib trial in February.

Benitec Biopharma

ASX Spotlight Conference book

Sector Commentary: | Pharmaceutical & healthcare | 13 Oct 2014

-

Simavita

Edison healthcare quarterly: It’s getting personal

Sector Commentary: | Pharmaceutical & healthcare | 30 Jun 2014

-

Bionomics

Poised for key RCC data

Update | Pharmaceutical & healthcare | 10 Mar 2014

Bionomics will shortly see the outcome of its Phase II study of its lead drug, the vascular disrupting agent (VDA) BNC105, in second-line renal cell carcinoma. In our view, this represents a major stock price catalyst. Bionomics has recently reported an encouraging response rate in the first stage of its separate Phase I/II trial of BNC105 in recurrent ovarian cancer. We have updated our current risk-adjusted NPV to A$338m, equivalent to A$0.80/share ahead of the outcome of BNC105 in RCC. We note that a positive outcome in the RCC study, and a move into Phase III, would potentially boost the valuation to c A$413m or A$0.99/share.

TESARO

Edison healthcare quarterly: A boost for allergy immunotherapy

Sector Commentary: | Pharmaceutical & healthcare | 05 Mar 2014

-

Anteo Diagnostics

ASX Spotlight Conference – London, 6 March 2014

Sector Commentary: | Pharmaceutical & healthcare | 04 Mar 2014

-

Bionomics

Eagerly awaited RCC data for BNC105

QuickView | Pharmaceutical & healthcare | 25 Feb 2014

Bionomics will shortly see the outcome of its Phase II study of its lead drug, the vascular disrupting agent (VDA) BNC105 in second-line renal cell carcinoma. In our view, this is likely to represent a major stock price catalyst. Bionomics has recently reported an encouraging response rate in the first stage of its separate Phase I/II trial of BNC105 in recurrent ovarian cancer. The company has a partnered programme with Ironwood Pharmaceuticals (IXW-2143, Phase I for anxiety) and a number of preclinical assets in cancer and CNS disease (with one CNS programme partnered with Merck & Co).

Doray Minerals

ASX Spotlight Conference – New York, 27 February 2014

Sector Commentary: | Pharmaceutical & healthcare | 24 Feb 2014

-

Futura Medical

Edison healthcare quarterly: Immuno-oncology 2: The combos come

Sector Commentary: | Pharmaceutical & healthcare | 06 Nov 2013

-

Bionomics

Option deal with Merck to address pain target

Update | Pharmaceutical & healthcare | 07 Aug 2013

Bionomics has signed an option and licensing agreement with Merck & Co covering the development of blockers of the Nav1.7 sodium channel for the treatment of chronic and neuropathic pain. The deal, which has an initial two-year research phase, has option exercise, development and regulatory milestones totalling up to US$172m. The new programme is in the early discovery phase and therefore does not affect our risk-adjusted NPV, which only considers Bionomics' clinical-stage programmes. Thus, we continue to value Bionomics at A$300m or A$0.72/share.